RCTs and RWD: What are They and How do They Complement Each Other in Cancer Research?
In this new blog series from COTA and Deloitte, we will explore the expanding role of real-world data in oncology.
Reflecting on Innovation and Hope during Blood Cancer Awareness Month
Every September, the healthcare, life sciences, and patient advocacy communities mark Blood Cancer Awareness Month, a time to focus on raising awareness about leukemia, lymphoma, myeloma, and other cancers that affect the blood or bone marrow.
With Tailored, Fit-for-Purpose RWD from COTA, Life Science Companies Can Drive Innovation
Innovation is the key to success in the life sciences industry. But with the vast amounts of data being generated by clinical trials and other research, it can be difficult to know where to focus your efforts. COTA’s tailored, fit-for-purpose real-world data (RWD) can help.
Summer Interns Explore Career Pathways, Pick Up New Skills from COTA Mentors
COTA’s Summer Internship Program provides an opportunity for college students to explore their career interests, learn new skills, and receive mentorship from experts in the field. This year’s interns come from a variety of backgrounds and majors, and are working in a number of different areas within COTA.
Envisioning the Future of Regulation for Artificial Intelligence in Healthcare
As artificial intelligence revolutionizes healthcare, we must develop a regulatory framework to ensure ethical use of patient data for research and care delivery. But, what should those guardrails look like, and how will we deploy them across the life sciences and clinical care industries? Miruna Sasu shares her thoughts on AI in healthcare and its efficacy with patient data.
The COTA Team Expands as Demand for RWD Surges
2022 has been a time of extraordinary growth at COTA including many new faces that we are proud to welcome to our team.
Noel Alaka Joins COTA’s Life Science Team to Accelerate Adoption of Oncology Real-World Data
After working at one of the world’s leading global clinical research organizations, Noel joins us to continue his work advocating for patients and helping to advance therapeutic and diagnostic options for all.
Making the Most of Real-World Data: Addressing Cancer Disparities Starts with All of Us
COTA President & CEO, Miruna Sasu, gave a keynote speech at the DIA 2022 Global Annual Meeting on healthcare disparities. She shared her personal story of how her family benefited from clinical trials and how she is now working to open those opportunities for others.
Meet Our Interns!
We are so excited to welcome our 8 new interns for our 2022 internship program – learn a little bit more about each the newest additions to COTA.
COTA Research Showcased High Concordance Rate Between Real-World Physician Response Assessment & the 2017 European LeukemiaNet (ELN) Criteria for Acute Myeloid Leukemia at EHA2022
COTA researchers and collaborators’s recent abstract in the European Hematology Association’s library, found that overall agreement between response categories was 65.1% among AML data.
